Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ASCO 2019 | Should we transplant or not in frontline therapy for MCL?

Tycel Phillips • 3 Jun 2019
ASCO 2019
Lymphoma Mantle Cell Lymphoma

Tycel Phillips, MD, of the University of Michigan, Ann Arbor, MI, discusses if we should transplant or not in frontline therapy for mantle cell lymphoma (MCL) at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.

More from Tycel Phillips

Retrospective study on outcomes and safety of covalent BTK inhibitors for the treatment of MCL
2:32
Retrospective study on outcomes and safety of covalent BTK inhibitors for the treatment of MCL
Tycel Phillips • 6 Dec 2025
Interim analysis of a Phase II study of the GLOVe regimen in untreated, high-risk MCL
3:24
Interim analysis of a Phase II study of the GLOVe regimen in untreated, high-risk MCL
Tycel Phillips • 6 Dec 2025
Long-term disease control associated with epcoritamab and CAR T-cell therapy in LBCL
2:15
Long-term disease control associated with epcoritamab and CAR T-cell therapy in LBCL
Tycel Phillips • 6 Dec 2025
The evolving paradigm of frontline DLBCL treatment: strategies being explored in trial
1:50
The evolving paradigm of frontline DLBCL treatment: strategies being explored in trial
Tycel Phillips • 6 Dec 2025

Related Videos

Time to third-line treatment after BR +/- acalabrutinib in previously untreated MCL: ECHO analysis
2:24
Time to third-line treatment after BR +/- acalabrutinib in previously untreated MCL: ECHO analysis
Tycel Phillips • 10 Dec 2025
Two-year follow-up from ZUMA-2: safety and efficacy of brexu-cel in R/R MCL
1:13
Two-year follow-up from ZUMA-2: safety and efficacy of brexu-cel in R/R MCL
Tycel Phillips • 10 Dec 2025
A novel cell model of pirtobrutinib-tolerant persister cells in mantle cell lymphoma
5:31
A novel cell model of pirtobrutinib-tolerant persister cells in mantle cell lymphoma
Tycel Phillips • 10 Dec 2025
Retrospective study on outcomes and safety of covalent BTK inhibitors for the treatment of MCL
2:32
Retrospective study on outcomes and safety of covalent BTK inhibitors for the treatment of MCL
Tycel Phillips • 6 Dec 2025
The content of VJHemOnc is intended for healthcare professionals